Tirzepatide + Retatrutide
Also known as: Tirz + Reta, Dual-agonist + triple-agonist blend
Pre-mixed metabolic blend combining tirzepatide, a GIP/GLP-1 dual receptor agonist, with retatrutide, an investigational GIP/GLP-1/glucagon triple receptor agonist, both acting on incretin pathways to reduce appetite and improve glucose handling and weight. Tirzepatide is FDA-approved as a finished prescription drug (Mounjaro/Zepbound) but combining it with retatrutide is not an approved use; retatrutide remains investigational in Phase 3 (Eli Lilly TRIUMPH, NDA anticipated late 2026). This specific blend is not an approved product and has no published controlled human efficacy or safety data — any rationale is inferred from the separate agents, and combination-specific human data is lacking.
Common research uses
Pricing for Tirzepatide + Retatrutide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
No sellers for Tirzepatide + Retatrutide are indexed yet — we add vendors and their prices as we find them.
COAs for Tirzepatide + Retatrutide
2 third-party tests across 1 vendor. Each card links to the full report.
15 citations indexed for Tirzepatide + Retatrutide
Study · 2026
Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
Incretin-based dual and triple agonists have emerged as effective options for obesity management, offering enhanced weight loss through multi-receptor agonism. However, data on their efficacy and safety remain limited.
review · 2026
Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy
Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs) and next-generation dual and triple agonists.
Study · 2026
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
review · 2026
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review
Purpose An increasing number of anecdotal reports on social media platforms and medical blogs describe dysesthesia, particularly burning skin sensations, in association with glucagon-like peptide-1 receptor (GLP-1R) agonists.
Study · 2026
The use of GLP-1 receptor agonists and co-agonists in adults without diabetes: a systematic review and network meta-analysis protocol
Background Despite the increasing clinical use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), head-to-head evidence across these agents remains limited.
review · 2026
Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now used widely to manage diabetes, obesity, and an expanding set of metabolic and cardiorenal conditions.
Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.